Esra Pinarbaş

Esra Pinarbaş

Auto-generated profile, based on publicly available information

Esra Pinarbaş

Recep Tayyip Erdoğan University, School of Medicine

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2021 in Online Türk Sağlık Bilimleri Dergisi
Verified
Journal Article
Open access
PDF file
SSSinan Saral
Sinan Saral
ATAtilla Topçu
Atilla Topçu
ASAYŞEGÜL SÜMER
AYŞEGÜL SÜMER
AKAli Koray Kaya
Ali Koray Kaya
AÖAykut Öztürk
Aykut Öztürk
EPEsra Pinarbaş
Esra Pinarbaş
Objective: The antidepressant agomelatine agent is a melatonin receptor (MT1 and MT2) agonist and a serotonin receptor (5-HT2C) antagonist. Increasing evidence shows that agomelatine has neuroprotective and neuromodulatory effects. In this study, the potential effects of agomelatine in rats with scopolamine-induced cognitive impairment were investigated.Materials and Methods: Adult male rats were administered scopolamine (1 mg/kg) and agomelatine (40 mg/kg) for 21 days. After drug administration, rats were subjected to new object recognition (NOR) and Morris water maze (MWM) tests in order to evaluate cognitive behaviors. In addition, brain-derived neurotrophic factor (BDNF) and acetylcholine (ACh) levels in the hippocampus and prefrontal cortex were evaluated.Results: Scopolamine significantly decreased both spatial memory and discrimination index (p0.05). In addition, agomelatine significantly increased BDNF levels in both hippocampus and prefrontal cortex compared to the scopolamine group (p<0.05, p0.05).Conclusion: Taken together, these results demonstrated that agomelatine plays a important role in alleviating scopolamine-induced memory impairment. Therefore, we suggest that agomelatine may be a potential agent in the prevention of cognitive impairment.